| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2011: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2009: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Research Abstract |
We analyzed the molecular mechanisms of blood-nerve barrier(BNB) malfunction in various neuropathies, using immortal cell lines of human BNB origin recently established in our laboratory. Sera from some group of patients with inflammatory neuropathies can destroy BNB. Advanced glycation end-products(AGE), the late products of non-enzymatic glycation increased in diabetic condition, are shown to impair BNB via upregulation of VEGF and TGF. Various transporters in the membrane of barrier-forming endothelial cells can be a appropriate target toward the novel therapeutics of intractable human peripheral nervous system disorders.
|
